MAPT and Alzheimer disease: Successful delivery of the antisense siRNA BACE and tau‐related fibril inhibitor peptide was achieved. Furthermore, the PEGylated dendrigraft poly‐l‐lysine nanoparticles significantly decreased positive BACE 1 signals and phosphorylated‐tau levels in AD mouse models.